单次分割前列腺特异性膜抗原正电子发射断层扫描和多参数磁共振成像引导的立体定向体部放疗治疗前列腺癌局部复发
分析2016至2020年64例PSMA-PET阳性前列腺癌局部复发患者接受单次分割SBRT的疗效与安全性,中位随访21.6个月。PSA水平在SBRT后下降(P=0.03),1、2、3年无进展生存率分别为85.3%、65.9%、51.2%,仅6例(9%)出现1或2级毒性,无高级别毒性。作者认为该治疗安全、高效且节省时间,可延迟ADT使用并可能避免部分患者接受前列腺床放疗。
要点
- 单次分割SBRT后PSA水平下降(P=0.03),随访期间检出3例局部复发。
- 1、2、3年无进展生存率分别为85.3%、65.9%、51.2%。
- 6例(9%)出现1或2级毒性,无高级别毒性;6例(9%)因疾病进展开始ADT。
核心结论
- 作者认为,这是首个单次分割、PSMA-PET和mpMRI引导的局灶性SBRT分析,结果令人鼓舞;该治疗似乎安全、高效且节省时间,即使在经过强化预治疗的患者中也是如此;复发导向治疗可延迟ADT的使用,并可能在选定患者中避免前列腺床放疗。
研究设计与样本
- 纳入2016年至2020年间接受单次分割SBRT治疗的PSMA-PET阳性前列腺癌局部复发患者,共64例。
- SBRT前治疗包括:31例根治性前列腺切除术(RP),18例体外放疗(EBRT)联合RP,5例EBRT,其余10例为其他联合治疗。
- SBRT时6例(9%)接受雄激素剥夺治疗(ADT)。
- 中位随访21.6个月;SBRT前中位PSA水平为1.47 ng/mL。
- 所有患者接受单次分割治疗,中位处方剂量为21 Gy,中位等剂量线为65%。
主要发现
- SBRT后PSA水平下降(P=0.03),随访期间检出3例局部复发。
- SBRT后1年、2年、3年无进展生存率分别为85.3%、65.9%、51.2%。
- 6例(9%)因疾病进展在SBRT后开始ADT;SBRT后1年、2年、3年新开始ADT的比率分别为1.8%、7.3%、22.7%。
- 6例(9%)出现1级或2级毒性;未观察到高级别毒性。
关键数值与推荐
- 单次分割SBRT的中位处方剂量为21 Gy,中位等剂量线为65%。
- SBRT后1年、2年、3年无进展生存率分别为85.3%、65.9%、51.2%。
- SBRT后1年、2年、3年新开始ADT的比率分别为1.8%、7.3%、22.7%。
- 1级或2级毒性发生率为9%(6例),未观察到高级别毒性。
临床怎么用
- 作者认为,单次分割、PSMA-PET和mpMRI引导的局灶性SBRT似乎是安全、高效且节省时间的治疗,即使在经过强化预治疗的患者中也是如此。
- 作者认为,复发导向治疗可延迟ADT的使用,并可能在选定患者中避免前列腺床放疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To analyse the efficacy and safety of focal prostate-specific membrane antigen positron emission tomography (PSMA-PET)- and multiparametric magnetic resonance imaging (mpMRI)-guided single-fraction stereotactic body radiotherapy (SBRT) for the treatment of prostate cancer (PCa) local recurrences. PATIENTS AND METHODS: Patients with PSMA-PET-positive PCa local recurrences treated with single-fraction SBRT between 2016 and 2020 were included. Identification for subsequent recurrences or metastatic spread based on increasing prostate-specific antigen (PSA) levels were evaluated using PSMA-PET imaging. RESULTS: A total of 64 patients were identified. Patients received various treatments before SBRT (31 patients with radical prostatectomy [RP], 18 external beam radiotherapy [EBRT] with RP, five EBRT, and the remaining 10 other combinations). The median follow-up was 21.6 months. The median PSA level before SBRT was 1.47 ng/mL. All patients received a single-fraction treatment with a median prescription dose and isodose line of 21 Gy and 65%, respectively. At the time of SBRT, six patients (9%) received an androgen deprivation therapy (ADT). PSA levels decreased after SBRT (P = 0.03) and three local recurrences were detected during the follow-up. The progression-free survival after 1-, 2-, and 3-years was 85.3%, 65.9%, and 51.2%, respectively. Six patients (9%) started ADT after SBRT due to disease progression. The rates of newly started ADT after 1-, 2-, and 3-years were 1.8%, 7.3%, and 22.7%, respectively. Grade 1 or 2 toxicities occurred in six patients (9%); no high-grade toxicity was observed. CONCLUSION: While the available data for SBRT in the PCa local recurrence setting describe outcomes for fractionated irradiations, the findings of this first analysis of single-fraction, PSMA-PET- and mpMRI-guided focal SBRT are encouraging. Such treatment appears to be a safe, efficient, and time-saving therapy even in intensively pretreated patients. Recurrence-directed treatments can delay the use of ADT and could avoid prostate bed irradiation in selected patients.
引用
- Ehret F, Hofmann T, Fürweger C, et al. Single-fraction prostate-specific membrane antigen positron emission tomography- and multiparametric magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer local recurrences. BJU Int. 2022. PMID: 36114771. doi:10.1111/bju.15894
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。